What happens when you take estrogen with dong quai?
Dong quai (Angelica sinensis) is a root used in traditional Chinese medicine for menstrual and menopausal symptoms. Modern laboratory studies have produced concerning findings about its estrogenic activity. According to Memorial Sloan Kettering Cancer Center's botanical reference, dong quai showed estrogen-agonist activity in vitro, stimulated proliferation of both estrogen receptor-positive (MCF-7) and estrogen receptor-negative (BT-20) breast cancer cells, and promoted the growth of estrogen receptor-positive breast tumors in a murine model. A water extract increased MCF-7 cell proliferation in a dose-dependent manner with or without added 17-beta-estradiol.
Dong quai also contains coumarin derivatives that can enhance the anticoagulant effect of warfarin. A published case report described a woman whose INR rose significantly after she started dong quai for menopausal symptoms while on warfarin. The bleeding risk normalized after she stopped the herb.
Why is this important?
Estrogen therapy, whether prescribed for menopausal symptoms (Premarin, estradiol patches, Estrace), for contraception (combined pills containing ethinyl estradiol), or as part of hormone therapy in transgender care, is dosed to achieve specific tissue exposures. Adding an herbal product with estrogen-agonist activity introduces an additional, unmeasured estrogenic signal that can compound effects in hormone-sensitive tissues including breast, endometrium, and possibly the venous wall.
For women with a personal or family history of breast cancer, endometrial cancer, ovarian cancer, or uterine fibroids, the issue is more acute. Memorial Sloan Kettering's guidance is direct: patients with hormone-sensitive cancers should consult with their physicians before using this herb. Most integrative oncologists go further and recommend avoidance.
The combined bleeding risk is also worth noting. Both estrogen therapy and dong quai can raise the risk of clotting or bleeding complications through different mechanisms; the net effect in any individual patient is hard to predict, especially in someone who is already on warfarin, a DOAC, or aspirin for cardiovascular protection.
What should you do?
Do not start dong quai while you are taking prescribed estrogen, and do not start estrogen while you are taking dong quai, without first discussing the combination with the clinician who manages your hormone therapy.
- Stop dong quai before starting hormone replacement therapy. Allow at least two weeks for clearance before beginning the prescription.
- If you are using dong quai to manage hot flashes, vaginal dryness, or other menopausal symptoms, ask your clinician about evidence-based alternatives that do not stimulate hormone-sensitive tissue. Options include low-dose vaginal estrogen for genitourinary symptoms, gabapentin or SSRIs for vasomotor symptoms, or cognitive behavioral therapy.
- If you have a history of breast, endometrial, or ovarian cancer, avoid dong quai entirely. The estrogen-agonist activity in tissue models is a strong reason to choose other options.
- If you are on warfarin, a direct oral anticoagulant (apixaban, rivaroxaban, edoxaban, dabigatran), or daily aspirin, avoid dong quai because of additive bleeding risk.
- Read multi-herb formulas carefully. Dong quai is a common component of "women's health" blends and may be present without being prominently advertised.
Which specific products are affected?
The interaction concern applies to all forms of prescribed estrogen, including oral estradiol or conjugated estrogens (Premarin), transdermal patches and gels (Climara, Vivelle-Dot, Divigel, EstroGel), vaginal estrogen products (Estring, Vagifem, Imvexxy, even though systemic absorption is low), and combined oral contraceptives. It also applies to selective estrogen receptor modulators (raloxifene, tamoxifen, bazedoxifene), which act on the same receptors that dong quai may stimulate.
Dong quai itself appears as standalone capsules (typical doses 500 to 600 mg one to three times daily) and as a component of menopausal symptom blends marketed under names such as Estroven, Remifemin Plus, and various "women's balance" or "menopause support" formulas. It also appears in traditional Chinese herbal decoctions where it is often combined with peony, ligusticum, and rehmannia.
The bottom line
Dong quai has demonstrated estrogen-agonist activity in tissue and animal studies, and it can promote growth of estrogen receptor-positive breast cancer cells. Adding it to prescribed estrogen creates an unnecessary and unmeasured layer of estrogenic stimulation. Women with hormone-sensitive cancer history should avoid dong quai. Those on anticoagulants should also avoid it because of bleeding risk. If you are looking for relief from menopausal symptoms, work with your clinician on options that do not stimulate hormone-sensitive tissue.